BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 27236153)

  • 1.  Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant.
    Sarkar M; Dodge JL; Roberts JP; Terrault N; Yao F; Mehta N
    Ann Hepatol; 2016; 15(4):545-9. PubMed ID: 27236153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
    Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
    Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
    Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation.
    Norman JS; Li PJ; Kotwani P; Shui AM; Yao F; Mehta N
    J Hepatol; 2023 Dec; 79(6):1469-1477. PubMed ID: 37683735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
    Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
    J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein.
    Agopian VG; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Cheng EY; Yersiz H; Farmer DG; Hiatt JR; Busuttil RW
    JAMA Surg; 2017 Jan; 152(1):55-64. PubMed ID: 27706479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.
    Hameed B; Mehta N; Sapisochin G; Roberts JP; Yao FY
    Liver Transpl; 2014 Aug; 20(8):945-51. PubMed ID: 24797281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.
    Mehta N; Heimbach J; Harnois DM; Sapisochin G; Dodge JL; Lee D; Burns JM; Sanchez W; Greig PD; Grant DR; Roberts JP; Yao FY
    JAMA Oncol; 2017 Apr; 3(4):493-500. PubMed ID: 27838698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence.
    Grąt M; Kornasiewicz O; Lewandowski Z; Hołówko W; Grąt K; Kobryń K; Patkowski W; Zieniewicz K; Krawczyk M
    World J Surg; 2014 Oct; 38(10):2698-707. PubMed ID: 24858191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma.
    Meischl T; Rasoul-Rockenschaub S; Győri G; Scheiner B; Trauner M; Soliman T; Berlakovich G; Pinter M
    United European Gastroenterol J; 2021 Mar; 9(2):209-219. PubMed ID: 32741316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of locoregional therapy and alpha-fetoprotein on outcomes in transplantation for liver cancer: a UNOS Region 6 pooled analysis.
    Wong LL; Naugler WE; Schwartz J; Scott DL; Bhattacharya R; Reyes J; Orloff SL
    Clin Transplant; 2013; 27(1):E72-9. PubMed ID: 23278701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-transplant alpha-fetoprotein is associated with post-transplant hepatocellular carcinoma recurrence mortality.
    Mahmud N; John B; Taddei TH; Goldberg DS
    Clin Transplant; 2019 Jul; 33(7):e13634. PubMed ID: 31177570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma.
    Kornberg A; Schernhammer M; Kornberg J; Friess H; Thrum K
    Dig Dis Sci; 2019 Jan; 64(1):269-280. PubMed ID: 30259282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
    J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-fetoprotein and
    Yang Z; Luo FZ; Wang S; Lerut J; Zhuang L; Li QY; Xu X; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):229-234. PubMed ID: 32303439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is serum alpha-fetoprotein useful for predicting recurrence and mortality specific to hepatocellular carcinoma after hepatectomy? A test based on propensity scores and competing risks analysis.
    Shim JH; Yoon DL; Han S; Lee YJ; Lee SG; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
    Ann Surg Oncol; 2012 Nov; 19(12):3687-96. PubMed ID: 22644512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era.
    Sharma P; Welch K; Hussain H; Pelletier SJ; Fontana RJ; Marrero J; Merion RM
    Dig Dis Sci; 2012 Mar; 57(3):806-12. PubMed ID: 21953139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time.
    Mehta N; Dodge JL; Grab JD; Yao FY
    Hepatology; 2020 Mar; 71(3):943-954. PubMed ID: 31344273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower Alpha-Fetoprotein Threshold of 500 ng/mL for Liver Transplantation May Improve Posttransplant Outcomes in Patients With Hepatocellular Carcinoma.
    Goldman ML; Zhou K; Dodge JL; Yao F; Mehta N
    Liver Transpl; 2022 May; 28(5):763-773. PubMed ID: 34927344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver transplantation for hepatocellular carcinoma: analysis of factors predicting outcome in 1074 patients in OPTN Region 5.
    Macdonald B; Sewell JL; Harper AM; Roberts JP; Yao FY
    Clin Transplant; 2015 Jun; 29(6):506-12. PubMed ID: 25777321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.